1
项与 HIV gp 140 adjuvanted with LTK63(Richmond Pharmacology) 相关的临床试验A Phase I, Open Label, Parallel Group Trial To Evaluate Safety And Immunogenicity Of Three Nasal Immunisations Using A Fixed Dose-Level Of HIV gp140 V2 Loop Deleted Protein Adjuvanted With LTK63 Followed By Intramuscular Boosting With HIV gp140 V2 Loop Deleted Protein Adjuvanted With MF59 When Administered To Healthy Adults
The purpose of this study is to determine whether an HIV vaccine given as three nasal immunisations with a protein from HIV virus mixed with a toxoid adjuvant, followed by two intramuscular immunisations with the same protein mixed with a liquid adjuvant, causes untoward adverse reactions when administered to healthy adult volunteers. An initial evaluation of immune responses to the vaccine will also be undertaken.
100 项与 HIV gp 140 adjuvanted with LTK63(Richmond Pharmacology) 相关的临床结果
100 项与 HIV gp 140 adjuvanted with LTK63(Richmond Pharmacology) 相关的转化医学
100 项与 HIV gp 140 adjuvanted with LTK63(Richmond Pharmacology) 相关的专利(医药)
100 项与 HIV gp 140 adjuvanted with LTK63(Richmond Pharmacology) 相关的药物交易